Decision time? Check out our latest product comparisons

HemoSep recovers blood during surgery to improve open-heart surgery prospects

By

September 6, 2012

HemoSep is an autotransfusion technology for open heart surgeries that can improve prospec...

HemoSep is an autotransfusion technology for open heart surgeries that can improve prospects for patients

A simpler, cheaper and more efficient method to recover blood lost during open heart and major trauma surgeries has been developed at the University of Strathclyde in Glasgow. Called HemoSep, the new approach has proven successful improving prospects for cardiac surgery patients during trials at the Kirikkale University Hospital in Ankara, Turkey. The technology is soon to be launched commercially.

HemoSep is an autotransfusion method, which concentrates cells from the blood spilled during surgery and recovers them for transfusion back to the patient. This is done with the help of blood bag that employs a chemical sponge technology. A mechanical agitator does the job of concentrating the blood taken from the site of the surgery or drained from the heart-lung machine after the surgery is finished. Finally, the patient receives the recovered blood through intravenous transfusion.

The clinical trials consisted of over 100 surgical procedures and HemoSep significantly reduced the need for blood transfusions, besides preserving normal clotting mechanisms. On top of that, the occurrence of inflammation, a common reaction after such procedures, was also reduced.

This method offers several advantages over traditional ones, mainly because it reduces need for donor blood and the risk of adverse reactions during transfusion, such as contamination and immunosuppression. It also simplifies the process. Traditional donor blood methods can be complex and costly, requiring a sophisticated centrifuge and a pumping machine that has to be operated by specialized technicians.

The team that developed the new method expects the technology will be adapted for open-heart surgery on children, who face greater risks during such procedures. They are positive the method could become standard during heart surgeries and there is also a possibility that it could be applied to blood preservation in cases of transplantation, orthopedics and neurosurgery.

HemoSep has received a CE mark, which means it can be sold to the health sector. The technology has been licensed to Advancis Surgical Ltd., and the company will commercialize the technology in the European Union, Canada, where it received national approval, and other regions that recognize the CE mark. The launch of the device is scheduled for September and further trials are also planned.

Source: University of Strathclyde

About the Author
Antonio Pasolini Brazilian-Italian Antonio Pasolini graduated in journalism in Brazil before heading out to London for an MA in film and television studies. He fell in love with the city and spent 13 years there as a film reviewer before settling back in Brazil. Antonio's passion for green issues - and the outdoors - eventually got the best of him and since 2007 he's been writing about alternative energy, sustainability and new technology.   All articles by Antonio Pasolini
2 Comments

Really nice and advanced product and very useful to humans i suggest this equipment should be in all surgeon hospitals it will rescue most valuable humans life. Thanks for sharing this most valuable information

jefffoxduct
6th September, 2012 @ 04:12 am PDT

Not very informative and somewhat misleading. Is this a rewrite of a press release? Autotransfusion is not a new or uncommonly used medical procedure, as the article seems to imply. Nor, as best I can tell from the article, is this device a new technology for an established medical procedure. Autotransfusion has been in widespread use since the late 1970's - early 1980's. There are numerous autotranfusion systems already in clinical use throughout the world. It is unclear from this article what advantages, if any, this device offers over devices already proven to be safe and effective. The comparisons mentioned in the article are unclear. Was the trial to prove the advantages of autotransfusion vs. donated blood, as the article seems to say? If so, that's an issue that was settled over 30 years ago. In any case, it would be considered malpractice, at least in the US, to withhold autotransfusion absent religious concerns on the part of the patient, particularly if the only reason was commercial. The only relevant and ethical comparison would be this device vs. a proven autotransfusion system. I would hope that was the situation here. In that case, the article doesn't explain why this device is any improvement over existing technology.

frog78
6th September, 2012 @ 10:10 am PDT
Post a Comment

Login with your gizmag account:

Or Login with Facebook:


Related Articles
Looking for something? Search our 29,042 articles